Lack of Value for Cisplatin Added to Mitomycin-Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized Trial
- 1 February 1987
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 10 (1) , 82-85
- https://doi.org/10.1097/00000421-198702000-00018
Abstract
Fifty-five patients with metastatic carcinomas of unknown primary site (50 adenocarcinomas) were randomized, after stratification, to treatment with either mitomycin and doxorubicin (MA) or mitomycin, doxorubicin, and cisplatin (MAP). There was a moderate but nonsignificant improvement in regression frequency (14 vs. 27%) and a slight but also nonsignificant worsening of survival (median 5.5 months vs. median 4.6 months) by the addition of cisplatin at 60 mg/m2 to the MA regimen.This publication has 4 references indexed in Scilit:
- Differing Response Rates and Survival Between Squamous and Non-Squamous Non-Small Cell Lung Cancer Comparison of CAP Versus MAPAmerican Journal of Clinical Oncology, 1986
- 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.Journal of Clinical Oncology, 1986
- CisplatinAnnals of Internal Medicine, 1984
- Evaluation of response criteria in advanced lung cancerCancer, 1979